Shanghai Henlius Biotech Inc. (HKG: 2696), a leading Chinese biotech company, has entered into a strategic partnership with AL-TIRYAQ AL-KHALAWI Medical Company (SVAX), a healthcare unit owned by the prominent Fakeeh family in Saudi Arabia, during the 2024 China International Import Expo (CIIE). This collaboration aims to leverage Henlius Bio’s expertise in biological drug R&D and production with SVAX’s local market access and commercialization strengths.
Integration of R&D and Market Access
The partnership will integrate Henlius Bio’s leading biological drug R&D and production capabilities with SVAX’s local registration, market access, and commercialization advantages in the Middle East North Africa and Turkey (MENAT) region. This synergy is expected to promote the global registration and commercialization of multiple Henlius Bio products, enhancing the accessibility of advanced biological drugs and benefiting patients in the region.
Joint Venture and Product Commercialization
Specifically, Henlius Bio and SVAX will establish a commercialization and manufacturing joint venture in Saudi Arabia. This joint venture will co-develop, locally register, manufacture, and commercialize Henlius Bio’s products, including HanDaYuan (adalimumab biosimilar) and Hanbeitai (bevacizumab biosimilar), in the MENAT region. This strategic move will ensure that these essential biological drugs are more accessible to patients in the region.
Investment in Biosimilar Development and Global Marketing
Furthermore, Henlius Bio and SVAX will jointly invest in the development of Henlius Bio’s HLX17, a biosimilar version of Merck, Sharp & Dohme’s Keytruda (pembrolizumab). The partnership will also cover global regulatory filing and marketing for this biosimilar, expanding its reach and potentially improving patient outcomes worldwide.-Fineline Info & Tech
Leave a Reply